Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials
   Google Scholar   
Citation:
J Clin Oncol vol 36 (15 suppl) abst 577
Meeting Instance:
ASCO 2018
Year:
2018
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3388  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821  
Corr. Author:
 
Authors:
                                         
Networks:
LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, PR028   
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: